Filing Details
- Accession Number:
- 0001567619-18-006564
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-16 19:14:57
- Reporting Period:
- 2018-11-14
- Accepted Time:
- 2018-11-16 19:14:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557533 | Robert Jeffrey Ajer | C/O Biomarin Pharmaceutical Inc., 105 Digital Drive Novato CA 94949 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-11-14 | 9,000 | $63.10 | 58,135 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-11-14 | 5,201 | $91.62 | 52,934 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-11-14 | 2,400 | $92.21 | 50,534 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-11-14 | 799 | $93.81 | 49,735 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-11-14 | 600 | $94.35 | 49,135 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy Common Stock) | Disposition | 2018-11-14 | 9,000 | $0.00 | 9,000 | $63.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,700 | 2014-12-04 | 2024-06-03 | No | 4 | M | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on September 10, 2018.
- The price in column 4 is the weighted average price. The price actually received ranged from $91.01 to $92.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The price actually received ranged from $92.01 to $92.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The price actually received ranged from $93.12 to $94.09. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The price actually received ranged from $94.13 to $94.66. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- Reflects the number of options outstanding after the transactions from this specific stock option grant.
Billionaire Hedge Funds
